Date: 2016-01-13
Type of information: Construction of a production plant
Compound:
Company: Lonza (Switzerland)
Therapeutic area: Technology - Services
Type agreement: expansion of a production plant
Action mechanism:
Disease:
Details: * On January 13, 2016, Lonza announced the expansion of mammalian production capacity at its Slough (UK) facility. Based on the increased demand for biopharmaceutical development and clinical manufacturing services, two 1000L single-use bioreactors will be installed at the site. This expansion will significantly increase the existing single-use manufacturing capacity in Slough while allowing current operations to continue without interruption. The additional mammalian manufacturing capacity is now available to customers.
Lonza’s cGMP facility in Slough provides cell line construction, process development and clinical manufacturing services for mammalian-derived biotherapeutics.
Financial terms:
Latest news:
